StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3061% below fair value
$2.96−0.38 (-11.23%)

Close on Nov 20, 2026Market cap $93.16MP/E –Yield –

LENZ Therapeutics gross profit

Gross profit is revenue minus the direct cost of the goods and services sold.

For fiscal 2025 it was $18.67M.

Annual gross profit

PeriodPeriod endValueChange
FY2025Dec 31, 2025$18.67M–
FY2024Dec 31, 2024$0–

Quarterly gross profit

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$5.21M–
Q1 FY2026Mar 31, 2026$825.00K–
Q2 FY2025Jun 30, 2025$5.00M–
Q1 FY2025Mar 31, 2025$0–

More LENZ Therapeutics figures

See a number that looks wrong?